12:00 AM
 | 
May 07, 2012
 |  BC Week In Review  |  Company News  |  Deals

Regeneron, Sanofi deal

Sanofi disclosed in its 1Q12 earnings that in February it terminated co-development of REGN475. Sanofi remains obligated to fund agreed-upon development costs through the end of 2012 and is eligible to receive a mid-single digit royalty. In...

Read the full 161 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >